Simvastatin
Brand names: Zocor · Active ingredient: Simvastatin
In short: Simvastatin is indicated: To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular dis
What is Simvastatin used for?
Simvastatin is indicated:
To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events.
As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C):
In adults with primary hyperlipidemia.
In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterol emia (HoFH).
As an adjunct to diet for the treatment of adults with:
Primary dysbetalipoproteinemia.
Hypertriglyceridemia.
Simvastatin dosage
For dosing with the 5 mg strength, use another simvastatin product.
Take simvastatin orally once daily in the evening.
The maximum recommended dosage is simvastatin 40 mg once daily . The simvastatin 80 mg daily dosage is restricted to patients who have been taking simvastatin 80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity .
If as dose is missed, take the missed dose as soon as possible. Do not double the next dose.
For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving simvastatin 40 mg daily, prescribe alternative LDL-C-lowering treatment.
Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating simvastatin, and adjust the dosage if necessary.
The recommended dosage range of simvastatin is 20 mg to 40 mg once daily.
The recommended dosage range of simvastatin is 10 mg to 40 mg daily.
For patients with severe renal impairment [creatinine clearance (CLcr) 15 – 29 mL/min], the recommended starting dosage of simvastatin is 5 mg once daily . Use another simvastatin product to initiate dosing in such patients .
There are no dosage adjustment recommendations for patients with mild or moderate renal impairment.
Concomitant use of simvastatin with the following drugs requires dosage modification of simvastatin .
Patients taking Lomitapide
Reduce the dosage of simvastatin by 50%. Do not exceed simvastatin 20 mg once daily (or 40 mg once daily for patients who have previously taken simvastatin 80 mg daily chronically while taking lomitapide) .
Patients taking Verapamil, Diltiazem, or Dronedarone
Do not exceed simvastatin 10 mg once daily.
Patients taking Amiodarone, Amlodipine, or Ranolazine
Do not exceed simvastatin 20 mg once daily.
How to take Simvastatin — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Myopathy and Rhabdomyolysis
Advise patients that simvastatin may cause myopathy and rhabdomyolysis. Inform patients taking the 80 mg daily dose of simvastatin that they are at an increased risk. Inform patients that the risk is also increased when taking certain types of medication or consuming grapefruit juice and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to inform other healthcare providers prescribing a new medication or increasing the dose of an existing medication that they are taking simvastatin. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever .
Hepatic Dysfunction
Inform patients that simvastatin may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice .
Increases in HbA1c and Fasting Serum Glucose Levels
Inform patients that increases in HbA1c and fasting serum glucose levels may occur with simvastatin. …
Warnings & precautions
Do not take this medicine if: Simvastatin is contraindicated in the following conditions:
Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) .
Concomitant use of cyclosporine, danazol or gemfibrozil .
Acute liver failure or decompensated cirrhosis .
Hypersensitivity to simvastatin or any excipients in Simvastatin Tablets. Hypersensitivity reactions, including anaphylaxis, angioedema and Stevens-Johnson syndrome, have been reported .
Simvastatin may cause myopathy and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including simvastatin.
In clinical studies of 24,747 simvastatin-treated patients with a median follow-up of 4 years, the incidence of myopathy, defined as unexplained muscle weakness, pain, or tenderness accompanied by creatinine kinase (CK) increases greater than ten times the upper limit of normal (10×ULN), were approximately 0.03%, 0.08%, and 0.61% in patients treated with simvastatin 20 mg, 40 mg, and 80 mg daily, respectively. In another clinical study of 12,064 simvastatin-treated patients (with a history of myocardial infarction) with a mean follow-up of 6.7 years, the incidences of myopathy in patients taking simvastatin 20 mg and 80 mg daily were approximately 0.02% and 0.9%, respectively. The incidences of rhabdomyolysis (defined as myopathy with a CK >40×ULN) in patients taking simvastatin 20 mg and 80 mg daily were approximately 0% and 0.4%, respectively . …
Simvastatin side effects
The following important adverse reactions are described below and elsewhere in the labeling:
Myopathy and Rhabdomyolysis
Immune-Mediated Necrotizing Myopathy
Hepatic Dysfunction
Increases in HbA1c and Fasting Serum Glucose Levels
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
In clinical studies, 2,423 adult patients were exposed to simvastatin with a median duration of follow-up of approximately 18 months. The most commonly reported adverse reactions (incidence ≥5%) in these simvastatin clinical studies were: upper respiratory infections (9%), headache (7%), abdominal pain (7%), constipation (7%), and nausea (5%). Overall, 1.4% of patients discontinued simvastatin due to adverse reactions. The most common adverse reactions that led to discontinuation were: gastrointestinal disorders (0.5%), myalgia (0.1%), and arthralgia (0.1%).
In a Cardiovascular Outcomes Study (the Scandinavian Simvastatin Survival Study [Study 4S]), adult patients (age range 35-71 years, 19% women, 100% Caucasians) were treated with 20-40 mg per day of simvastatin or placebo over a median of 5.4 years ; adverse reactions reported in ≥2% of patients and at a rate greater than placebo are shown in Table 1. …
Drug interactions
Simvastatin is a substrate of CYP3A4 and of the transport protein OATP1B1. Simvastatin exposure can be significantly increased with concomitant administration of inhibitors of CYP3A4 and OATP1B1. Table 2 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with simvastatin and instructions for preventing or managing them .
Strong CYP3A4 inhibitors
Clinical Impact: | Simvastatin is a substrate of CYP3A4. Concomitant use of strong CYP3A4 inhibitors with simvastatin increases simvastatin exposure and increases the risk of myopathy and rhabdomyolysis, particularly with higher simvastatin dosages.
Intervention: | Concomitant use of strong CYP3A4 inhibitors with simvastatin is contraindicated . If treatment with a CYP3A4 inhibitor is unavoidable, suspend simvastatin during the course of strong CYP3A4 inhibitor treatment.
Examples: | Select azole anti-fungals (e.g., itraconazole, ketoconazole, posaconazole, and voriconazole), select macrolide antibiotics (e.g., erythromycin and clarithromycin), select HIV protease inhibitors (e.g., nelfinavir, ritonavir, and darunavir/ritonavir), select HCV protease inhibitors (e.g., boceprevir and telaprevir), cobicistat-containing products, and nefazodone. …
About this medicine
Simvastatin is a prodrug of 3-hydoroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that is derived synthetically from a fermentation product of Aspergillus terreus.
Simvastatin is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetra- hydro-4hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1α,3α,7β,8β(2S*,4S*),-8aβ]]. The empirical formula of simvastatin is C25H38O5 and its molecular weight is 418.57. Its structural formula is:
Simvastatin is a white to off-white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c85d6d02-6cf6-4995-a590-cfca302ea0c9. Read the full official label on DailyMed.
Related medicines
Atorvastatin Amlodipine Lisinopril Losartan Metoprolol Rosuvastatin Spironolactone Pravastatin